Rule 3.19A.2

# Appendix 3Y

# Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Elixinol Wellness Limited
ABN:	621 479 794

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Helen Wiseman
Date of last notice	6 January 2023

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A	
Date of change	1) 26 May 2023 2) 31 May 2023	
No. of securities held prior to change	280,132 Fully paid Ordinary Shares 1,043,424 Performance Share Rights	
Class	<ol> <li>Fully paid Ordinary Shares</li> <li>Director Fee rights</li> </ol>	
Number acquired	<ol> <li>1) 555,556 Fully paid Ordinary Shares</li> <li>2) 3,055,556 Director Fee rights</li> </ol>	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ol> <li>Ordinary Shares - \$0.018 per share</li> <li>Director Fee rights - issued in lieu of cash consideration with a deemed issue price of \$0.018 per Director Fee Right.</li> </ol>	

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	835,688 Fully paid Ordinary Shares 1,043,424 Performance Share Rights 3,056,556 Director Fee rights	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol> <li>Fully paid ordinary shares issued under the Company's Share Purchase Plan</li> <li>Issue of Director Fee rights approved by shareholders at the Company's Annual General Meeting on 31 May 2023</li> </ol>	

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

## Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

<sup>+</sup> See chapter 19 for defined terms.

If prior written clearance was provided, on what date was this	N/A
provided?	

<sup>+</sup> See chapter 19 for defined terms.